Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Erasca (Nasdaq: ERAS) closed an upsized public offering of 25,875,000 shares of common stock on January 23, 2026, which included 3,375,000 shares sold pursuant to the underwriters' full exercise of their option.

Rhea-AI Summary

Erasca (Nasdaq: ERAS) closed an upsized public offering of 25,875,000 shares of common stock on January 23, 2026, which included 3,375,000 shares sold pursuant to the underwriters' full exercise of their option.

The shares were sold at $10.00 per share, generating approximately $258.8 million in gross proceeds before underwriting discounts, commissions, and offering expenses. All shares were sold by Erasca.

Erasca intends to use net proceeds, together with existing cash and marketable securities, to fund research and development of its product candidates, development programs, working capital, and other general corporate purposes.

Positive

• Raised approximately $258.8 million in gross proceeds
• Proceeds earmarked to fund R&D and development programs
• Underwriters fully exercised 3,375,000 share option

Negative

• Issued 25,875,000 new shares, diluting existing shareholders
• Underwriting discounts and offering expenses will reduce net proceeds

Argus Jan 26 session

-3.51% close to close Open Argus

Details

News Market Reaction – ERAS

On Jan 26, the first trading day after this news, ERAS closed 3.51% below the previous close.

Data tracked by StockTitan Argus for the Jan 26 session.

Market Context

This announcement confirms the closing of ERAS’s upsized equity offering at $10.00 per share, totali...

Analysis

This announcement confirms the closing of ERAS’s upsized equity offering at $10.00 per share, totaling 25,875,000 shares and gross proceeds of $258.8 million. The deal was executed under an existing Form S-3 shelf, following earlier proposed and priced-offering updates. Investors may track how these funds support clinical programs and corporate needs, as well as any further use of the remaining shelf and related prospectus capacity.

Key Figures

Shares offered: 25,875,000 shares Underwriters’ option: 3,375,000 shares Offering price: $10.00 per share +2 more

Shares offered

25,875,000 shares

Total common stock in upsized public offering, including option shares

Underwriters’ option

3,375,000 shares

Additional shares sold via full exercise of underwriters’ option

Offering price

$10.00 per share

Public offering price for common stock in this deal

Gross proceeds

$258.8 million

Gross proceeds before underwriting discounts and expenses

Shelf effective date

August 22, 2025

Date Form S-3 shelf registration statement was declared effective

Previous Offering Reports

2 past events · Latest: Jan 21

Same Type 2 events

1. Jan 21

   Offering priced

   24h Move

   +2.5%

   Upsized offering of 22,500,000 shares priced at $10.00 per share.

2. Jan 20

   Offering proposed

   24h Move

   +2.0%

   Proposed $150.0M common stock offering with 30-day underwriter option.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

public offering, underwriters’ option, shelf registration statement, form s-3, +2 more

6 terms

public offering financial

"closed its previously announced upsized public offering of 25,875,000 shares"

A public offering is when a company sells shares to the general public through the stock market, either by issuing new shares to raise cash or by letting existing owners sell their stakes. Think of it like a business opening its doors to many new owners at once: it can bring in money for growth but also increases the number of shares available, which can change the stock price and dilute existing ownership — key factors investors watch closely.

underwriters’ option financial

"including 3,375,000 shares sold pursuant to the underwriters’ full exercise"

An underwriters’ option is a provision in a securities offering that lets the group selling the new shares buy a fixed extra amount (often up to 15%) from the issuer after the sale. It acts like a short-term safety valve: if demand is strong, underwriters exercise the option and supply extra shares; if the price falls, they can use the option to stabilize the market. For investors this matters because it affects how many shares come to market, potential short-term dilution, and post-offering price stability—similar to having a reserve supply to smooth out sudden swings.

shelf registration statement regulatory

"offered by Erasca pursuant to a shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"shelf registration statement on Form S-3, including a base prospectus"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

base prospectus regulatory

"on Form S-3, including a base prospectus, that was previously filed"

A base prospectus is a detailed document that provides essential information about a financial offering, such as a bond or share issue. It acts like a comprehensive guide for investors, explaining what the investment involves, the risks involved, and how the process works. This helps investors make informed decisions before committing their money.

prospectus supplement regulatory

"A final prospectus supplement relating to this offering has been filed"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has closed its previously announced upsized public offering of 25,875,000 shares of its common stock, including 3,375,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares. The shares of common stock were sold to the public at a price of $10.00 per share. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $258.8 million. All of the shares of common stock sold in the public offering were sold by Erasca.

Erasca intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities, to fund the research and development of its product candidates and other development programs and for working capital and other general corporate purposes.

J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI acted as joint book-running managers for the offering.

The securities described above were offered by Erasca pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the Securities and Exchange Commission (SEC) and was declared effective on August 22, 2025.

A final prospectus supplement relating to this offering has been filed with the SEC. The offering was made only by means of a prospectus supplement and accompanying prospectus. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; and Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com. Electronic copies of the final prospectus supplement and accompanying prospectus are also available on the website of the SEC at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Forward Looking Statements
Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: our expectations regarding the anticipated use of proceeds from the public offering. Actual results may differ from those set forth in this press release due to the risks and uncertainties associated with market conditions, as well as risks and uncertainties inherent in our business described in our prior filings with the SEC, including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2024, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact:

Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Source: Erasca, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Erasca (ERAS) sell in the January 23, 2026 offering?

Erasca sold 25,875,000 shares, including 3,375,000 shares under the underwriters' option.

What was the offering price per share for Erasca (ERAS) on January 23, 2026?

The public offering price was $10.00 per share.

How much gross proceeds did Erasca (ERAS) raise from the offering?

The offering generated approximately $258.8 million in gross proceeds before fees and expenses.

What will Erasca (ERAS) use the net proceeds from the offering for?

Erasca intends to use net proceeds for research and development, development programs, working capital, and general corporate purposes.

Who were the joint book-running managers for Erasca's (ERAS) offering?

J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI acted as joint book-running managers.